Impact of baseline GLP-1 receptor agonist use on albuminuria reduction and safety with simultaneous initiation of finerenone and empagliflozin in type 2 diabetes and chronic kidney disease (CONFIDENCE Trial)
Agarwal R, Green JB, Heerspink HJL, et al.
Diabetes Care. Pub. online 19 Sep 2025.
Leggi


